


DRSTM

Alternative.
Legal.
Solutions.


Phase 5 IM – Market Survey

May 2019


(1) Which of the following do you perceive to be the biggest challenge in implementing IM?




(2) Various Phase 5 impact-mitigation strategies. Which do you believe has the best chance of being enacted?




(3) In light of recent BCBS/IOSCO (& CFTC) guidance which of the following strategies would you consider adopting to track IM exposures?




(4) Given BCBS/IOSCO guidance at what level of IM exposure would you consider starting to negotiate IM documentation?




(5) How will your firm deal with the IM documentation challenge?




(6) Do you have a preference as to IM Documentation Suite - Phase 1 or Next Generation?




(7) Which of these platforms would you consider using?




(8) How do you intend to operate/monitor SIMM?




(9) What is your preferred choice of custodian model?



(10) How do you intend to deal with custodian onboarding/KYC?



(11) Which collateral assets do you wish to post/receive?



Have your say...

Please add your own responses to the survey at:

<https://www.surveymonkey.com/r/2JMLBR6>



Alternative.
Legal.
Solutions.

Jonathan Martin
Director, CEO

M +44 (0)7866 591 383

D +44 (0)20 3617 6663

E jonathan.martin@drs-als.com

London Office

20 St Dunstan's Hill, London EC3R 8ND

Newcastle Office

Unit 8, Hoults Yard, Walker Road, Newcastle-upon-Tyne NE6 2HL

T +44 (0)20 3597 5979

drs-als.com